Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.39 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855959 | 0.95 | KDM1A (0.47) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL3215690 | 0.94 | MAPK8 (0.51) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL29442098 | 0.93 | KDM1A (0.47) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL7351804 | 0.93 | MAPK8 (0.41) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL7351817 | 0.93 | MAPK8 (0.41) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL29607893 | 0.92 | KDM1A (0.48) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL30658576 | 0.92 | KDM1A (0.51) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL31696335 | 0.90 | KDM1A (0.54) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL3865485 | 0.89 | MAPK8 (0.50) | KDM1AMAPK8MAPK9MAPK10MAOB | |
| SCHEMBL31165809 | 0.89 | MAPK8 (0.45) | KDM1AMAPK8MAPK9MAPK10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605453-B2 | CP2C-targeting peptide-based anticancer agent | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2026-04-21 | — | — | US | disclosed |
| US-20230078718-A1 | UNSATURATED FATTY ACID-CONJUGATED CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-4101470-A1 | UNSATURATED FATTY ACID-CONJUGATED CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | Industry-University Cooperation Foundation Hanyang University (KR) | 2022-12-14 | — | — | EP | disclosed |
| CN-115361975-A | Anticancer agent based on unsaturated fatty acid conjugated CP2C targeting peptide | 汉阳大学校产学协力团 | 2022-11-18 | — | — | CN | disclosed |
| EP-4005583-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | Industry - University Cooperation Foundation Hanyang University (KR) | 2022-06-01 | — | — | EP | disclosed |
| US-20220160888-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160888-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | SREBF2, BCLAF1, CIP2A | KDM1A 3703/4885MAPK8 4181/4885MAPK9 4371/4885 |
| US-20230078718-A1 | UNSATURATED FATTY ACID-CONJUGATED CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | ZDHHC2, FFAR2, SLC27A2 | KDM1A 3454/4885MAPK8 2769/4885MAPK9 4053/4885 |
| US-12605453-B2 | CP2C-targeting peptide-based anticancer agent | SREBF2, SLC27A2, ZDHHC2 | KDM1A 598/4885MAPK8 3817/4885MAPK9 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.